Archive for February, 2010

Voluntary System Works For Swine Flu Vaccination

February 10th, 2010 -- Posted in Immune System | No Comments »

Social interaction between neighbours, work colleagues and other communities and companionable groups makes unforced vaccination programs by reason of epidemics such as Swine Flu, SARS or Bird Flu a surprisingly effective process of illness control.

New research published today, Thursday 11 February, in New Journal of Physics (co-owned by means of the Institute of Physics and German Physical Society), shows that contact with others can positively influence individuals to choose unconstrained vaccination while considering the pros and cons.

The group of Chinese researchers found that in scale-free networks – social networks through one not exactly divisible by 2 distribution of connectedness in the same state as neighbourhoods, labor places or gyms – the so-called hub nodes, people with multiple social connections, tend to single out to inoculate with kine-pox themselves taken in the character of they are at higher risk of infection from others, to this degree containing the spread of epidemics.

Based in succession their studies, the researchers have observed that at the beginning of an prevalent, when levels of contagion are oppressive, a wide number of people will gradually suppose vaccination. As the movables of the of short duration vaccination wear off, a second wave of outbreak have being inclined occur, howsoever adhering a less amount severe level due to the number of individuals with still effective immunisation.

This is why outbreaks of distemper and voluntary vaccination occur periodically, eventually settling down to a stable state. Individuals with a large social reticulated flutter a crucial role in this period as, given information on the spread of the illness is freely available, the majority of them leave choose spontaneous vaccination.

In order to prescribe up an effectual vaccination generalship it is consequently crucial to feign the nave nodes’ willingness to vaccinate, which can potentially be negatively influenced by factors such as the jeopardy of virus, the coverage of disease and the cost of vaccination.

As the researchers write, “Sometimes the high costs of vaccination or misunderstanding the side drift of vaccinations can shorten the enthusiasm for taking vaccination. In this subject of discussion the external incentives such as aid of vaccination require to be paid would have being helpful in enhancing the vaccination trending of the hub nodes.”

The researchers’ paper can be downloaded free at http://www.iop.org/EJ/abstract/1367-2630/12/2/023015

Source:
Joseph Winters
Institute of Physics

Fox on Sex: Vibrators – A Girl’s Friend or Foe?

February 9th, 2010 -- Posted in Health News | No Comments »

“Can I meeting you through reference to vibrator addiction?”

I had to crack a smile when I got this request from a journalist. What’sitting the angle for this story? The customary drill involves questions liking: Are only the staid and lonely susceptible? Does using this sex toy mystify the risk of partner replacement? Can a woman honestly become out-of-control through this ground-moving wonder?

When it comes to vibrator employment, many worry or bewilderment. if it will be a gal’sitting ultimate sex demise. Sure, it’session providing her through profusion of pleasure now. But the kind of if she be able to’t win enough? What on the supposition that she becomes addicted? What if she wants nothing else on the other hand that vibrator — by or independently of a lover?

It’sitting hard to disturbance of strata a woman for wanting her vibe. Not only is it a trustworthy date that’s everything about her pleasuring, but the orgasms induced can be more of high and swiftly attainable. It’s also time efficient, doesn’t require getting everything dolled up and can’privately break her heart.

Still, it’s those very benefits that invite the scrutiny. The vibe is seen taken in the character of a substitute, a immorality that power of choosing cause her to shelter into the depths of bed, merely to surface for new batteries or another source of energy grant. Surely, addiction is inevitable, right?

First, let’s subsist free. There is nonentity harmful, bad or unhealthy about using a vibrator. That said, there may be cases to which place a woman has a difficult delivery reaching gradual culmination – solo or for the time of partnered sex – without this gadget. There are a couple of major reasons on the side of this:

— Clitoral stimulation. The vibrator provides direct and sturdy sensations to the 8,000 fortify endings in her crown jewel. This area is often not given enough attention or stimulated effectively for the time of other types of sex play.

— Body response. You have qualified your corpse to respond in a certain path. Vibrator or not, when you promise in the like type of stimulation, you habituate your sexual response. Your body learns to respond in a never-failing way to a definite pattern. It can subsist herculean to elicit a replication, like orgasm, doing anything outside of that routine.

To withdraw from keep clear of vibrator “enslavement,” you long for to eschew getting into a routine. As is the plight with coupled sex, slip on’privately let yourself get into a rut. Change up what you’re doing. Get creative. Try different positions. Or give the vibe a rest and use your hands, or lose yourself in fantasies instead of physical sensations.

But only grant that you want to …

After all, there’sitting nothing bad with using a vibrator each time you have sex. Why should using a vibe religiously exist any contrary from using lube every time you’re suggest with yourself or some other? Who says that you shouldn’face to face?

Dr. Yvonne K. Fulbright is a sex educator, relationship expert, columnist and founder of Sexuality Source Inc. She is the writer of several books including, “The Better Sex Guide to Extraordinary Lovemaking.”

Journal Of Clinical Investigation Online News Feb. 8, 2010

February 8th, 2010 -- Posted in Immune System | No Comments »

NEPHROLOGY: New draw nigh to treating the kidney indisposition Alport syndrome?

Alport syndrome is a progressive hereditary kidney malady with no definitive therapy. It is caused by mutations in any of the collagen IV genes (COL4A3, COL4A4, and COL4A5). Motoko Yanagita and colleagues, at Kyoto University Graduate School of Medicine, Japan, have now identified a role for the protein USAG-1 in the unravelling of disease in mice that mould Alport syndrome (Col4a3-/- mice). As deletion of Usag1 in Col4a3-/- mice led to substantial attenuation of infirmity progression, preservation of kidney function, and extension of life span, the authors suggest that inhibiting USAG-1 might be a promising curative approach for the treatment of Alport syndrome.

TITLE: Loss of the BMP antagonist USAG-1 ameliorates ailment in a peer model of the progressive hereditary kidney disease Alport syndrome

AUTHOR CONTACT: Motoko Yanagita Kyoto University Graduate School of Medicine, Kyoto, Japan.

View this article at: http://www.jci.org/articles/view/39569?guide=c3580c682d75b2b119bd

HEMATOLOGY: Role for the protein HIF-2-alpha in Chuvash polycythemia

Individuals with a predicament known in the same proportion that Chuvash polycythemia, which is caused by a specific change in the protein VHL, have a greater proportion of their blood volume occupied by means of red blood cells than do in good case individuals. They besides have pulmonary hypertension (i.e., increased kindred pressure in the kindred vessels that pass to and from the lung) and increased respiratory rates, although the mechanistic basis since these symptoms has not been determined. Now, Celeste Simon and colleagues, at the University of Pennsylvania School of Medicine, Philadelphia, have identified a role with regard to the protein HIF-2-alpha in the lung complications of Chuvash polycythemia by means of studying mice that plan the predicament. Of particular touch, HIF-2-alpha activity was found to be increased in lungs from mice that model Chuvash polycythemia. Further, as loss of one copy of the gene amenable for generating HIF-2-alpha in mice that imitation Chuvash polycythemia suppressed the couple the polycythemia and pulmonary hypertension, the authors suggest that inhibiting HIF-2-alpha might cater a new approach to treat Chuvash ailment.

TITLE: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice

AUTHOR CONTACT: M. Celeste Simon University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

View this article at: http://www.jci.org/articles/view/36362?guide=78a2f13d85364cc6f65c

ONCOLOGY: Rab25: a suppressor of tumor formation in insides?

Colorectal adenocarcinoma accounts for the majority of cases of colorectal cancer. A course of genetic mutations in the cells lining the colon (intestinal epithelial cells) is pondering to be the cause of colorectal adenocarcinoma. By studying mouse models of colon cancer and tissue from individuals with colorectal adenocarcinoma, James Goldenring and colleagues, at Vanderbilt University School of Medicine, Nashville, be seized of now identified RAB25 as one gene that might be involved in the arrangement of colorectal adenocarcinomas.

Initial parsing indicated that pervading effect of Rab25 was solidly decreased in human colon adenocarcinomas compared by normal colon and that lower Rab25 expression predicted shorter indulgent survival times. To come up in continuance these data, which suggested that Rab25 functions of the same kind with a tumor suppressor (that is, a protein that when expressed at bring down than normal levels due to mutation of the gene responsible for its formation fails to debar tumors forming) in intestinal epithelial cells, the authors analyzed Rab25-deficient mice. Although these animals showed none gross abnormalities, when they were crossed with mice that model a ancestral syndrome that predisposes to colon cancer (ApcMin/+ mice), the Rab25-deficient ApcMin/+ mice developed increased numbers of of the intestines polyps and colonic tumors compared with cherishing ApcMin/+ mice. Similar results were obtained in a backer mouse image of colorectal adenocarcinoma, providing further settlement of the probable tumor suppressor role of Rab25 in intestinal epithelial cells.

TITLE: Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated by human colorectal adenocarcinomas

AUTHOR CONTACT: James R. Goldenring Vanderbilt University School of Medicine, Nashville, TN, USA.

View this article at: http://www.jci.org/articles/view/40728?clew=23ce364555ecb5bda924

IMMUNOLOGY: Complete chemokine profile of a cell

Chemokines are a large group of proteins whose predominant function is to aim confined apartment migration. They manage many physiological and pathophysiological processes, in strange in the immune system. Dirk Homann and colleagues, at University of Colorado Denver, Aurora, have it being so that developed a simple method to efficiently ascertain to be the same all the chemokines produced by a single cell stamp, something that has not been possible before.

The method developed by dint of. Homann and colleagues is a flow cytometry-based assay that uses commercially beneficial chemokine-specific antibodies to efficiently find out in the reach cells 37 of 39 pry about chemokines. Using this technique, the creator were good to delineate the complete chemokine profiles of couple types of immune elementary corpuscle (NK cells and B cells) in response to major polyclonal stimuli and to assess the chemokine response of immune cells known for example DCs to bacterial infection. Importantly, the authors were practical to adapt the method to resolve chemokine expression in full of heart cells, principal them to suggest that this process devise helper researchers understand the roles of chemokines in health and disease.

TITLE: Comprehensive assessment of chemokine effective exhibition profiles by melt cytometry

AUTHOR CONTACT: Dirk Homann University of Colorado Denver, Aurora, CO, USA.

View this heading at: http://www.jci.org/articles/view/40645?guide=3ba73571f42f82ed7858

Source:
Karen Honey
Journal of Clinical Investigation

For Obese, Vaccine Needle Size Matters

February 6th, 2010 -- Posted in Health News | No Comments »

NEW YORK —  Our ever-expanding waistlines may have outgrown the doctor’s needle, researchers declare, in the sort of could have being one greater degree of casualty of the corpulency general.

In a recent study, the researchers report that using a colors 1-inch needle to immunize portly adolescents against hepatitis B virus produced a abundant weaker effect than using a longer needle.

“As obesity rises in the U.S., we need to be observant that the criterion of be disposed may have to change to protect stout youth,” study co-author Dr. Amy Middleman of Baylor College of Medicine in Houston told Reuters Health.

Over three years her team vaccinated 22 young women and sum of two units young men in the shoulder, randomly assigning them to be injected with either a 1-inch or a 1.5-inch needle.

Once injected, vaccines trigger production of inconsiderable molecules called antibodies, which kick-start our immune system if we are ever attacked by the poison once additional.

The pair groups turned out to have different antibody counts depending on the needle used. In those injected with the short one, the number was almost halved.

Although everyone in the study had enough antibodies to be considered protected against hepatitis B, a let down add to the number generally means a not to such a degree much boisterous response.

“It gives us other evidence of the importance of choosing the not oblique needle length,” before-mentioned Middleman, “because we just slip on’t know what the impact could be in other vaccines.”

The results are no surprise, uttered Dr. Gregory Poland, who studies vaccines at the Mayo Clinic in Rochester, Minnesota. For years, doctors have known that vaccines attend to not to labor in the same manner with well in heavy people. Whether the obese take weaker immune systems, or greasy keeps shorter needles from reaching muscles, where the vaccines can affect immune cells, was unclear.

The elementary of the hepatitis B vaccine in the 1980s offered some clues. Soon after doctors began using the vaccine, they realized that it was failing to protect more female nurses.

At the time, the shot was given in the buttock, Poland told Reuters Health, and was thwarted by the padding there.

Instead of entering the muscle taken in the character of it was supposed to, the vaccine apparently was abrupt down in the fat tissue, where it had slight fall out to alter immune cells. So doctors began giving the shot in the less-padded shoulder.

With the fleshiness epidemic after this adding extra insulation to the projection, “our needles are going to subsist favored with to be longer,” Poland aforesaid.

And those long needles aren’t at the same time that unpleasant as they sound. In fact, Poland said, “they turn without to be less painful and be under the necessity existence under the necessity fewer side goods.”

The Centers for Disease Control and Prevention recommends longer needles in fleshy patients, but it is unclear how frequent doctors follow these guidelines, or even know about them.

Women are more affected by dint of. needle length than men, because their fat partition is different. But even obese women shouldn’privately be overly concerned until more research has been concluded, Middleman cautioned.

“Should you fare back and get all your immunizations repeated?” she before-mentioned, “No, I don’familiarily think so.”

QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients

February 6th, 2010 -- Posted in Immune System | No Comments »

Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned helping of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they wish entered into some agreement to expand a compeer diagnostic ground of admission kit during PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial articles of agreement of the diagnostic agreement have existence in possession of not been disclosed.

On April 16, 2008, Pfizer and Celldex Therapeutics, Inc. entered into an agreement to bestow Pfizer either invidiously choice worldwide allow to PF-04948568 (CDX-110) what one. is publicly in Phase 2 clinical development for the usage of newly diagnosed GBM.

Glioblastoma multiforme is the most customary malignant pristine brain tumor in adults and occurs in in a circle 25,000 patients worldwide each year. Pfizer’s investigational drug PF-04948568 (CDX-110) is a peptide vaccine which targets the tumor-specific Epidermal Growth Factor Receptor variant III (EGFRvIII), a mutated form of the epidermal growth factor receptor that is only present in cancer cells and occurs in 25-40 percent of GBM tumors. The QIAGEN assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment.

The EGFRvIII partner characteristic pleasure exist developed and manufactured at QIAGEN’s Center of Excellence for Companion Diagnostics in Manchester, UK. The diagnostic will subsist a real-time PCR assay used to detect EGFRvIII RNA in tumor combination. The assay is designed to tender a downright workflow, what one. supports its clinical utility in routine variation testing.

Commenting put on this announcement, Dr. Stephen Little, Vice President Personalized Healthcare, as antidote to QIAGEN, said, “We are very pleased to have signed this agreement with Pfizer, as it is another important stone’s throw toward the realization of personalized medicine. QIAGEN is aligned to deliver consort diagnostics to our pharmaceutical partners and this share is further evidence of our commitment to develop our philosophical and operational capabilities to save select the erect lenient for the right remedy.”

“We look forward to collaborating through QIAGEN’s DxS unit in the development of this grave distinguishing hireling that could potentially help physicians better limit the most appropriate usage for patients who suffer from glioblastoma multiforme,” uttered Garry Nicholson, president and general manager of Pfizer’session Oncology Business Unit.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and progressive growth of innovative usage options to gain the sight towards cancer patients worldwide. Our strong pipeline, one of the greatest number robust in the industry, is studied through precise focus on identifying and translating the most good scientific breakthroughs into clinical perseverance for patients across a wide range of cancers, including breast, lung, prostate, sarcoma, melanoma, and various hematologic cancers. Pfizer Oncology Pfizer Oncology has greater degree of than 32 biologics and trivial molecules in clinical development and additional than 200 clinical trials underway.

By working collaboratively through academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to method of treatment or control cancer with breakthrough medicines, to deliver the right drug for the straight invalid at the rectilinear time.

About Pfizer Inc: Working together for a healthier world&drive a trade;

At Pfizer, we apply science and our global pecuniary means to improve freedom from disease and well-being at every stagehouse of period of life. We strive to set the standard for gentry, safety and value in the discovery, development and manufacturing of medicines for the sake of people and animals. Our diversified global health circumspection portfolio includes of man and created being biologic and small molecule medicines and vaccines, as well being of the class who nutritional products and many of the world’s best-known consumer products. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

About QIAGEN

QIAGEN N.V., a Netherlands holding circle and the leading global provider of sample and assay technologies. The Company’session products are sold to corpuscular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers and embody one of the broadest panels of corpuscular diagnostic tests like antidote to prevention, profiling and personalized healthcare available worldwide.

About QIAGEN and Personalized Healthcare: QIAGEN is a chief company providing molecular diagnostics to back doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, QIAGEN and it’s wholly owned aiding, DxS supports the growth and sales of targeted cancer therapies by providing biomarkers and companion diagnostics. The Company has a continually expanding portfolio, principally notably including the TheraScreen® and Pyromark assay lines.. The TheraScreen® expedition of CE-marked clinical diagnostic kits can identify genetic tumor mutations that are serviceable in the decision of whether a patient may respond to specific cancer therapies, to this degree enabling doctors to provide the most advantageous usage. The portfolio includes two clinical diagnostic kits, K-RAS and EGFR.* The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA), two drugs used for the treatment of colorectal cancer. In addition, QIAGEN has created a portfolio of personalized healthcare assays for the PyroMark real time full sequence resolution platform.

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of February 4, 2010. Pfizer assumes no covenant to update forward-looking statements contained in this release since the outcome of new information or future events or developments.

This release contains forward-looking complaint that involves substantial risks and uncertainties about a product candidate, PF-04948568 (CDX-110), including its potential benefits, at the same interval that happy to the degree that an agreement between Pfizer and Qiagen to develop a diagnostic test kit to help select patients who might benefit from such product candidate. Such risks and uncertainties embody, among other things, the uncertainties native in mix with drugs exploration and development and in the development of diagnostic test kits; decisions by regulatory authorities regarding whether and at the time to approve in the same state diagnostic test kit and any drug applications that may be filed since such issue aspirant, similar to healthy because their decisions concerning labeling and other matters that could affect the availability or trading potential of such product aspirant; and based on rivalry developments.

A farther description of risks and uncertainties can be found in Pfizer’sitting Annual Report steady Form 10-K for the financial year ended December 31, 2008 and in its reports on Form 10-Q and Form 8-K.

QIAGEN SAFE HARBOR STATEMENT

Statements contained in this let loose that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: skill of progress and between nations operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic careful search, proteomics, women’sitting health/HPV testing, corpuscular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors’ products, emporium taking of our products, and integration of acquired technologies and businesses. For further information, refer to our filings through the SEC, including our latest Form 20-F. Information in this release is considered in the state of of the date of the release, and we undertake no duty to update this information unless required by principle.

In the United States, both test kits are available for examination use only. They have not been cleared or approved by authorities including the United States Food and Drug Administration or in some degree other regulatory intervention in the United States for human diagnostic or other clinical appliance, and is not intended and should not be used because full of heart diagnostic or any other clinical purposes.

Source: Pfizer Inc

View drug information in continuance Erbitux; Vectibix.

New Report Finds Low Adult Vaccination Rates For Pneumonia In U.S.

February 4th, 2010 -- Posted in Immune System | No Comments »

A newly come report, Adult Immunization: Shots to Save Lives, released by the Trust for America’sitting Health (TFAH), the Infectious Diseases Society of America (IDSA), and the Robert Wood Johnson Foundation (RWJF) erect that more than 30 percent of adults ages 65 and older had not been immunized in opposition to pneumony in 36 states in the same proportion that of 2008. The U.S. Centers during the term of Disease Control and Prevention (CDC) and other experts praise that the whole of seniors should be vaccinated against inflammation of the lungs, that is a one-time shot for most individuals, since seniors who get the seasonal flu are at risk since developing pneumonia as a complication.

Nationally, 33.1 percent of seniors had not been immunized counter to pneumonia, and just in the narrate from common side the highest immunization duty – Oregon – more than human centre of life separate into parts (26.8 percent) of seniors were not immunized. Washington, D.C. had the lowest number of seniors immunized, with nearly moiety (45.6 percent) of seniors not immunized.

Overall, the Adult Immunization report found millions of American adults go free from routine and recommended vaccinations each year, which leads to each estimated 40,000 to 50,000 preventable deaths, thousands of preventable illnesses, and $10 billion in preventable health care costs each year. In addition to low rates of pneumonia immunizations, only 2.1 percent of eligible adults be delivered of had the spasm, diphtheria, and whooping cough vaccine; only 10 percent of eligible adult women have had the human papillomavirus (HPV) vaccine; and only 36.1 percent of all adults were vaccinated for the seasonal flu in 2008.

“Thousands of lives could be saved each year allowing that we could increase the number of adults who embrace routine and recommended vaccinations,” said Jeffrey Levi, PhD, Executive Director of TFAH. “We necessity a national strategy to make vaccines a regular part of medical care and to educate Americans about the effectiveness and safety of vaccines.”

“Today, the remarkable majorship of vaccine-preventable diseases, hospitalization and deaths arise amidst adults. This is mournful, because currently-available vaccines can prevent many of these illnesses,” said William Schaffner, MD, FIDSA, chairman of IDSA’sitting Immunization Work Group and co-author of the communication.

The report identified several key reasons why person of mature age vaccination rates remain low in the United States despite the recommendation of medical experts, including:

  • Limited access: Most adults are outside of institutionalized settings, like the military or colleges, where vaccines be possible to subsist required;

  • Limited concern and insurance coverage: Primary and preventive care notwithstanding adults is limited, particularly for the uninsured and underinsured;
  • Limited financing for immunizations: Many adults have medical insurance that does not pay for vaccines and their administration, so out-of-pocket costs may be restrictive for many individuals;
  • Misunderstanding and misinformation: Many adults are misinformed about the security and effectiveness of vaccines; and
  • Limited research and development: Vaccine research, development, and fruit have been limited in the United States notwithstanding decades.

“This rural parts has a three-decker arrangement in the place of immunizing children, but too many adults are falling through the cracks,” said Richard J. Whitley, MD, FIDSA, president of IDSA. “Clearly, we destitution to build a advantage system in opposition to immunizing adults.”

“Thousands of adults die each year from vaccine preventable diseases, yet adult vaccination rates remain low,” reported Litjen (LJ) Tan, MS, PhD, Director of Medicine and Public Health toward the American Medical Association. “The hale condition care common can take a outstrip role in raising immunization rates by dint of. educating their grown-up person patients on the safeness and efficacy of vaccines and letting them know that getting vaccinated is one of the best ways to protect themselves and loved ones from disease.”

The report outlines a number of policy recommendations to increase rates of adult vaccinations. Some acme recommendations include:

  • Close coverage gaps: Providers should be required to offer full coverage for all vaccines recommended by the Advisory Committee on Immunization Practices (ACIP); Medicare should full cover the whole of recommended vaccinations under Part B; and a Vaccines for Uninsured Adults (VFUA) Program should have existence created to cover all adults who are uninsured.

  • Consider post-health amendment scenarios: As somewhat vaccine-related provisions are being phased in, steps should too be taken to fill out support of existing of age vaccine programs during the interim confinement preceding these proposals are in filled effect, and a Vaccines concerning Uninsured Adults (VFUA) Program would placid need to be created to be equal to adults who determine continue uninsured about rectify.
  • Increase public schooling: CDC and topical and state hale condition departments should receive increased resources to bring into being and manage large public education campaigns targeted at improving adult immunization rates, including communicating about the effectiveness and safety of vaccines.
  • Increase provider and patient denunciation: Standard practices should be developed to review patients’ immunization histories and vaccinations should subsist offered at appropriate of medicine encounters, of the like kind as during physicals, cancer screenings, and pre-natal visits. Health providers should also play every increased role in reducing transmission of disease and estimate some example by complying by the recommended vaccines to protect themselves, their staffs, and their patients.
  • Increase research, progressive growth, and production: The National Institutes of Health (NIH), CDC, and the U.S. Food and Drug Administration (FDA) should contain increased resources for vaccine research and development, including security direction and research, and incentives should be by stipulation for development and research in the United States to assure supplies of vaccines, especially for the time of times of emergency.

The full report is available forward TFAH’s Web site at http://www.healthyamericans.org, IDSA’s Web site at http://www.idsociety.org, and RWJF’s Web site at http://www.rwjf.org. The report was supported by the agency of a grant from RWJF.

Percent of Seniors NOT Vaccinated Against Pneumonia by State

Rates listed are the number of adults aged 65 and older who have not been vaccinated adverse to inflammation of the lungs. 1= Lowest vaccination rate; 51 = Highest vaccination defame. Rankings are based on combining three years of facts (2006-2008) from the U.S. Centers for Disease Control and Prevention’session Behavioral Risk Factor Surveillance System to “stabilize” data for comparison purposes. The pneumococcal vaccine is a one-time shot.

1. District of Columbia (45.6%); 2. Illinois (40.4%); California (39.0%); 4. Florida (37.6%); 5. New York (36.7%); 6. New Jersey (36.5%); 7. Texas (36.3%); 8. (manacle) Alabama (36.0%), Alaska (36.0%), Georgia (36.0%), and South Carolina (36.0%); 12. Arkansas (35.8%); 13. New Mexico (35.4%); 14. (bind) Idaho (35.3%) and South Dakota (35.3%); 16. Kentucky (34.8%); 17. Tennessee (34.6%); 18. Michigan (34.2%); 19. (tie) Maryland (33.9%) and Nevada (33.9%); 21. Louisiana (33.7%); 22. Connecticut (33.4%); 23. Mississippi (33.2%); 24. (complicate) Indiana (33.1%) and West Virginia (33.1%); 26. Missouri (32.7%); 27. Hawaii (32.1%); 28. Utah (32.0%); 29. Virginia (31.9%); 30. Arizona (31.8%); 31. Ohio (31.6%); 32. Kansas (31.5%); 33. North Carolina (31.2%); 34. Vermont (31.0%); 35. North Dakota (30.6%); 36. Massachusetts (30.4%); 37. Pennsylvania (30.3%); 38. (tie) Delaware (30.0%) and Washington (30.0%); 40. Iowa (29.9%); 41. Nebraska (29.8%); 42. Wyoming (29.7%); 43. (hold) Maine (29.5%) and Wisconsin (29.5%); 45. Minnesota (29.2%); 46. Oklahoma (28.9%); 47. (tie) Montana (28.8%) and New Hampshire (28.8%); 49. Rhode Island (28.2%); 50. Colorado (27.4%) and 51. Oregon (26.8%).

Source:
John Heys
Infectious Diseases Society of America

Judge: Complex Legal Issues Surround 11-Year-Old Mother

February 3rd, 2010 -- Posted in Health News | No Comments »

For many 10 and 11-year-old girls, life is all here and there talking to their friends, learning the lyrics to the latest Taylor Swift song and fabrication plans to go on foot to the mall. But, what happens when a child that young goes down the road of each adult?

It’s happened in the Northeast where one 11-year-old girl just became a mother. She gave offspring to a infant. boy this week, becoming one of the youngest mothers in the history of the United States. And at present that she is a mother – does that mean she’session technically some adult who be possible to fabricate grown up decisions?

Judge Andrew Napolitano, Fox News’ higher judicial analyst answered a few legal questions for FoxNewsHealth.com.

Q: What is the law whereas a minor gets pregnant?

A: A mother who is a minor has the same rights of motherhood — the right to make unfettered decisions about the raising of the chit — because an grown-up person mother, depending upon her period and level of maturity. The courts have several rules of thumb that they follow. If the minor is 12-years-old or younger, she is presumed to deficit the maturity to confer the part of unfettered child-rearing decisions; and the place where the baby was delivered is obliged to deliver the minor and the baby into the hands of a competent adult who agrees in writing to be a guardian and to inform the minor that she must live with and make child-rearing decisions in connective particle by the tutelary saint.

Q: What allowing that the child is between the ages of 12 and 16?

A: If the mother is 16 or older, she is presumed to be mature enough to raise the child unimpeded by a preserver or any flatter and the standing that delivers the baby is unimpeded to hand the infant. to the minor alone. If the mother is between 12 and 16, it is the what one ought to do of the physicians who delivered the baby to involve the mother with a protector who choose live through her, or to entreat a flatter of competent jurisdiction to readiness the difficulty, depending immediately after the physicians’ belonging to sentiment of the minor’s aim of maturity and access to material resources.

Q: Are there exceptions?

A: Note that the scenario above presents purely guidelines and presumptions, not hard and swift rules of body of rules. Thus, for case in point, it is theoretically potential that a 10- year-old could obtain the maturity to raise a bantling unimpeded by means of a tutelary saint (though, I discern of none case that has fix this to be such); and it is theoretically possible that a 16-year-old may require a full-time guardian (I comprehend of many cases that stand despite this). There are many other lawful obligations imposed upon physicians who discharge babies from minors, but they do not wrap the emancipation of the chief.

Q. What exactly does emancipation rascally?

A: The paragraph above provides guidelines for the ages of release for less mothers. “Emancipation” in this words immediately preceding means that a bantling is no longer subject to her parents and is free to bright and to raise her children while she wishes.

PATH To Pay FDA $480,000 To Speed Creation Of Pneumococcal Vaccine For Developing World

February 2nd, 2010 -- Posted in Immune System | No Comments »

The FDA on Monday said it’s entering into a collaboration through the nonprofit arrange PATH “to speed creation of a pneumococcal vaccine for children in developing nations,” United Press International reports (2/1).

“The bacteria, Streptococcus pneumoniae, can cause ruinous infections of the sense of hearing, lungs, blood and brain; worldwide, it kills almost one million children a year,” the New York Times writes. According to the FDA, PATH, which receives funding from the Bill & Melinda Gates Foundation, volition be remunerative the operation $480,000 to perform a elucidation step needed to build the vaccine, the New York Times reports (McNeil, 2/1).

According to each FDA press release, its mete “is to improve the efficiency of a elucidation technology in the development of pneumococcal conjugate vaccine candidates. The technology is used to conjoin a piece of the bacterium’sitting surface coating, a polysaccharide made up of long chains of sugars, to a especial molecule called a carrier protein in a process called conjugation. When carrier proteins are joined with the polysaccharides, they significantly increase the energy of the immune response (2/1).

“While it out of the way since a government agency to exist paid by a charity, the labor is vital principle done below a regulation that lets federal laboratories speed outside research in more cases,” the New York Times writes of the arrangement. “Ultimately, the plan is for the vaccine to be manufactured by the China National Biotec Group, which makes 80 percent of China’s vaccines, and the hope is that it volition be approved by the World Health Organization” (2/1).

This information was reprinted from globalhealth.kff.org by kind permission from the Henry J. Kaiser Family Foundation. You be possible to look on the full Kaiser Daily Global Health Policy Report, search into the archives and sign up on this account that email travail at globalhealth.kff.org.

© Henry J. Kaiser Family Foundation. All rights reserved.

« Prev